T time for tumors

No therapeutic cancer vaccine has yet shown sufficient efficacy to be approved in the U.S., in part because of the complex immune response to vaccination.A study in Cancer Cell helps refine the tactics for developing pancreatic cancer vaccines, showing that local activity by tumor-seeking helper T cells can retard-or promote-tumor development.¹

The study, conducted by a team led by Martin Rcken, professor of dermatology at Eberhard Karls University, could help cancer vaccine makers design therapies that direct T cells to the right place and elicit the right kind of immune response...